🇺🇸 FDA

Intelligence · Clinical Pipeline

GSK Glaxo Smith Pipeline

All ClinicalTrials.gov programs at GSK Glaxo Smith — phase, modality, and trial IDs.

Programs
205

Quick answer

GSK Glaxo Smith has 205 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. SB497115

    GlaxoSmithKline

    Purpura, Thrombocytopaenic, Idiopathic

    phase 2 small molecule completed

    1 trial

  2. SB497115

    GlaxoSmithKline

    Thrombocytopaenia

    phase 2 small molecule completed

    1 trial

  3. SERETIDE Rotacaps

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  4. Sodium Chloride Intravenous Infusion (0.9% w/v), BP, Benlysta 400 mg powder for concentrate for solution for infusion.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  5. Solabegron

    GlaxoSmithKline

    Overactive Bladder

    phase 2 small molecule completed

    1 trial

  6. Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  7. albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 2 mab completed

    1 trial

  8. dabrafenib

    GlaxoSmithKline

    Solid Tumours

    phase 2 small molecule completed

    1 trial

  9. meningococcal ACWY (vaccine)

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 mab completed

    1 trial

  10. pazopanib (GW786034)

    GlaxoSmithKline

    Neoplasms, Uterine Cervix

    phase 2 small molecule completed

    1 trial

  11. pazopanib (GW786034) 400 mg

    GlaxoSmithKline

    Neoplasms, Breast

    phase 2 small molecule completed

    1 trial

  12. sterile saline solution (0.9% w/v solution of NaCl in water).

    GlaxoSmithKline

    Urinary Tract Infections

    phase 2 small molecule active

    1 trial

  13. 50mg Ezogabine/retigabine

    GlaxoSmithKline

    Epilepsy

    phase 1 small molecule completed

    1 trial

  14. A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  15. A Phase 1 study of GSK5764227 in participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  16. A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  17. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

    GlaxoSmithKline

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  18. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  19. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  20. A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9)

    GlaxoSmithKline

    Multiple Myeloma

    phase 1 other active

    1 trial

  21. A study for GSK3862995B in healthy participants and participants with Chronic Obstructive Pulmonary Disease

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 other active

    1 trial

  22. A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  23. A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-134a (reference) in healthy participants aged 18 to 55 inclusive.

    GlaxoSmithKline

    Healthy volunteers

    phase 1 other active

    1 trial

  24. A study to compare the relative potency of salbutamol administered via metered dose inhalers containing propellants HFA-152a to HFA-134a in mild asthmatics aged 18 to 65 inclusive.

    GlaxoSmithKline

    Mild Asthma

    phase 1 other active

    1 trial

  25. A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.

    GlaxoSmithKline

    Kidney Disease

    phase 1 other active

    1 trial

  26. A study to investigate the pharmacokinetics of a combined oral contraceptive when given alone and in combination with GSK3036656 in female participants of non-childbearing potential aged 18 to 65 years of age

    GlaxoSmithKline

    Tuberculosis

    phase 1 other active

    1 trial

  27. A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  28. A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 other active

    1 trial

  29. A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  30. A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

    GlaxoSmithKline

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  31. Chloroquine

    GlaxoSmithKline

    Malaria

    phase 1 small molecule completed

    1 trial

  32. Daprodustat 2 mg tablet

    GlaxoSmithKline

    Anaemia

    phase 1 small molecule completed

    1 trial

  33. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  34. GSK2269557 ELLIPTA DPI

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  35. GSK2879552

    GlaxoSmithKline

    Leukaemia, Myelocytic, Acute

    phase 1 small molecule terminated

    1 trial

  36. GSK525762

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule terminated

    1 trial

  37. GSK5533524

    GlaxoSmithKline

    Neoplasms

    phase 1 small molecule active

    1 trial

  38. Lamivudine

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  39. New formulation

    GlaxoSmithKline

    Herpes Labialis

    phase 1 small molecule completed

    1 trial

  40. Pazopanib

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 1 small molecule completed

    1 trial

  41. Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  42. Poliorix

    GlaxoSmithKline

    Poliomyelitis

    phase 1 mab completed

    1 trial

  43. Prednisolone

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  44. SB-659032

    GlaxoSmithKline

    Atherosclerosis

    phase 1 small molecule completed

    1 trial

  45. Test Montelukast

    GlaxoSmithKline

    Respiratory Disorders

    phase 1 small molecule completed

    1 trial

  46. Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule active

    1 trial

  47. Amoxicillin/clavulanate

    GlaxoSmithKline

    Focal Infection, Dental

    approved small molecule completed

    1 trial

  48. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does GSK Glaxo Smith have?

205 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.